This guidance is a representation of the FDA’s current thinking how manufacturers and distributors of prescription human and animal drug products and medical devices can respond to unsolicited requests for information about unapproved or uncleared indications or conditions of use (off label information).

This updates previous guidance and clarifies FDA’s policies, in light of emerging electronic media.

Full guidance reproduced below: